JPY 2094.0
(0.24%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 12.4 Billion JPY | 9.22% |
2022 | 11.35 Billion JPY | 18.78% |
2021 | 9.56 Billion JPY | 1.44% |
2020 | 9.42 Billion JPY | -3.63% |
2019 | 9.78 Billion JPY | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 3.41 Billion JPY | 12.16% |
2023 Q3 | 3.06 Billion JPY | -3.64% |
2023 Q2 | 3.18 Billion JPY | 2.35% |
2023 Q4 | 3.04 Billion JPY | -0.81% |
2023 FY | 12.4 Billion JPY | 9.22% |
2023 Q1 | 3.11 Billion JPY | 3.77% |
2022 Q3 | 2.94 Billion JPY | 8.3% |
2022 FY | 11.35 Billion JPY | 18.78% |
2022 Q4 | 2.99 Billion JPY | 1.7% |
2022 Q2 | 2.72 Billion JPY | 0.0% |
2021 FY | 9.56 Billion JPY | 1.44% |
2020 FY | 9.42 Billion JPY | -3.63% |
2019 FY | 9.78 Billion JPY | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Pharma Foods International Co., Ltd. | 62.14 Billion JPY | 80.038% |
Takeda Pharmaceutical Company Limited | 4263.76 Billion JPY | 99.709% |
Sumitomo Pharma Co., Ltd. | 314.55 Billion JPY | 96.056% |
Shionogi & Co., Ltd. | 435.08 Billion JPY | 97.149% |
Wakamoto Pharmaceutical Co.,Ltd. | 7.73 Billion JPY | -60.317% |
Nippon Shinyaku Co., Ltd. | 148.25 Billion JPY | 91.632% |
Kaken Pharmaceutical Co., Ltd. | 72.04 Billion JPY | 82.78% |
Eisai Co., Ltd. | 741.75 Billion JPY | 98.327% |
Hisamitsu Pharmaceutical Co., Inc. | 141.7 Billion JPY | 91.245% |
Mochida Pharmaceutical Co., Ltd. | 102.88 Billion JPY | 87.942% |
Fuso Pharmaceutical Industries,Ltd. | 55.4 Billion JPY | 77.609% |
Nippon Chemiphar Co., Ltd. | 30.74 Billion JPY | 59.653% |
Tsumura & Co. | 150.84 Billion JPY | 91.776% |
Kissei Pharmaceutical Co., Ltd. | 75.57 Billion JPY | 83.585% |
Torii Pharmaceutical Co., Ltd. | 54.63 Billion JPY | 77.294% |
Towa Pharmaceutical Co., Ltd. | 227.93 Billion JPY | 94.557% |
Fuji Pharma Co., Ltd. | 40.88 Billion JPY | 69.659% |
Zeria Pharmaceutical Co., Ltd. | 75.72 Billion JPY | 83.617% |
KYORIN Holdings, Inc. | 119.53 Billion JPY | 89.621% |
Taiko Pharmaceutical Co.,Ltd. | 5.04 Billion JPY | -146.151% |
Daito Pharmaceutical Co.,Ltd. | 46.89 Billion JPY | 73.545% |
SymBio Pharmaceuticals Limited | 5.58 Billion JPY | -121.944% |
MedRx Co., Ltd | 26 Million JPY | -47615.385% |
Mizuho Medy Co.,Ltd. | 10.98 Billion JPY | -12.887% |
Solasia Pharma K.K. | 617 Million JPY | -1910.697% |
Modalis Therapeutics Corporation | - JPY | -Infinity% |
ASKA Pharmaceutical Holdings Co.,Ltd. | 62.84 Billion JPY | 80.259% |
Sawai Group Holdings Co., Ltd. | 176.86 Billion JPY | 92.985% |
Cyfuse Biomedical K.K. | 61.11 Million JPY | -20200.432% |
Toho Holdings Co., Ltd. | 1476.71 Billion JPY | 99.16% |
Koa Shoji Holdings Co.,Ltd. | 22.13 Billion JPY | 43.951% |